Artemisinin-type drugs for the treatment of hematological malignancies R. I. MancusoM. A. FoglioS. T. Olalla Saad Review Article 03 November 2020 Pages: 1 - 22
Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs Rajendar K. MittapalliDonghua YinRameshraja Palaparthy Review Article 25 November 2020 Pages: 23 - 30
Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin Helena TaflinElisabeth OdinYvonne Wettergren Original Article Open access 24 October 2020 Pages: 31 - 41
An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib Chenxiang WangLili YingZiye Zhou Original Article 10 November 2020 Pages: 43 - 52
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies Shigehisa KitanoToshio ShimizuTasha Sims Original Article Open access 04 November 2020 Pages: 53 - 64
Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial) Satoshi SaiMasanori ToyodaHironobu Minami Original Article 24 October 2020 Pages: 65 - 71
Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy Daiki TsujiMegumi MatsumotoKunihiko Itoh Original Article 24 October 2020 Pages: 73 - 83
Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin Yulin XuShichong LiaoShan Zhu Original Article 07 November 2020 Pages: 85 - 93
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients Marina MacchiniUmberto PerettiMichele Reni Original Article 06 November 2020 Pages: 95 - 101
HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer Fei-fei HanLu-lu RenLi-hong Liu Original Article 03 November 2020 Pages: 103 - 112
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis Salvador FudioJosep TaberneroValentina Boni Original Article Open access 27 October 2020 Pages: 113 - 124
MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma Long YangZheyue YuanLianjiang Wang Original Article 03 November 2020 Pages: 125 - 134
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma Tracy Murray StewartDaniel Von HoffRobert A. Casero Jr. Original Article 19 November 2020 Pages: 135 - 144
Correction to: Successful management of hyperammonemia with hemodialysis on day 2 during 5‑fluorouracil treatment in a patient with gastric cancer: a case report with 5‑fluorouracil metabolite analyses Yoshinao OzakiHirotaka ImamakiNorihiko Watanabe Correction Open access 12 November 2020 Pages: 145 - 145